Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article NY-ESO-1 immunotherapy for multiple myeloma.
Academic Article A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
Academic Article CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Academic Article NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Concept Antibodies, Neoplasm
Concept Antibodies
Concept Antibodies, Monoclonal
Concept Antibodies, Bispecific
Concept Antibodies, Monoclonal, Humanized
Concept Antibodies, Neutralizing
Academic Article Engineering more efficacious antibody therapy for myeloma.
Academic Article Siltuximab for multicentric Castleman disease.
Academic Article Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Academic Article Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article Immunologic approaches for the treatment of multiple myeloma.
Academic Article Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Academic Article Daratumumab for POEMS Syndrome.
Academic Article Infectious and immunological sequelae of daratumumab in multiple myeloma.
Academic Article International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Academic Article Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
Academic Article Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Academic Article Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
Academic Article Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Academic Article Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.
Academic Article Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Academic Article Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Academic Article Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
Academic Article Perspectives on the Treatment of Multiple Myeloma.
Academic Article Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria
  • Antibodies